{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:12Z","timestamp":1783075932774,"version":"3.54.6"},"reference-count":24,"publisher":"Royal College of Psychiatrists","issue":"5","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":9743,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1991,5]]},"abstract":"<jats:p>The levels of fluphenazine and fluphenazine sulphoxide in schizophrenic patients who were randomly assigned to receive either 5 mg or 25 mg of fluphenazine decanoate every two weeks were monitored. Patients treated with 25 mg of fluphenazine decanoate required three months to reach a steady-state plasma level, indicating that those patients who are being converted from oral to depot fluphenazine should continue to receive oral supplementation during the first three months of treatment with fluphenazine decanoate. Plasma levels of fluphenazine sulphoxide were lower than levels of fluphenazine. At six and nine months following randomisation, there was a statistically significant relationship between lower fluphenazine plasma levels and an increased risk of psychotic exacerbations. A relatively weak relationship was found between fluphenazine plasma levels and akinesia, but non-significant relationships between fluphenazine levels and other neurological side-effects including akathisia, retardation, and tardive dyskinesia. Monitoring the plasma levels may be helpful to clinicians who are attempting to treat stabilised patients with the lowest effective dose of fluphenazine decanoate.<\/jats:p>","DOI":"10.1192\/bjp.158.5.658","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T17:57:06Z","timestamp":1224093426000},"page":"658-665","source":"Crossref","is-referenced-by-count":46,"title":["Plasma Levels of Fluphenazine in Patients Receiving Fluphenazine Decanoate Relationship to Clinical Response"],"prefix":"10.1192","volume":"158","author":[{"given":"Stephen R.","family":"Marder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal K.","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore Van","family":"Putten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manickam","family":"Aravagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Hawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Mckay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Mintz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000023783_ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0920-9964(88)90025-4"},{"key":"S0007125000023783_ref12","doi-asserted-by":"publisher","DOI":"10.1007\/BF00441937"},{"key":"S0007125000023783_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0278-5846(83)90068-4"},{"key":"S0007125000023783_ref6","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198802000-00010"},{"key":"S0007125000023783_ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790070083010"},{"key":"S0007125000023783_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330021002"},{"key":"S0007125000023783_ref22","volume-title":"The Measurement and Classification of Psychiatric Symptoms","author":"Wing","year":"1974"},{"key":"S0007125000023783_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/BF00422403"},{"key":"S0007125000023783_ref18","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1962.10.3.799"},{"key":"S0007125000023783_ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000468580"},{"key":"S0007125000023783_ref5","first-page":"50","article-title":"Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approachers","volume":"45","author":"Ereshefsky","year":"1984","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000023783_ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290090008002"},{"key":"S0007125000023783_ref24","first-page":"346","article-title":"Changing from oral to depot fluphenazine","volume":"49","author":"Yadalam","year":"1988","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000023783_ref1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1980"},{"key":"S0007125000023783_ref21","first-page":"173","article-title":"Haloperidol plasma levels and clinical response: a therapeutic window relationship","volume":"24","author":"Van Putten","year":"1988","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000023783_ref17","doi-asserted-by":"publisher","DOI":"10.1007\/BF00187259"},{"key":"S0007125000023783_ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1987.01800180028005"},{"key":"S0007125000023783_ref14","first-page":"370","article-title":"Fluphenazine plasma levels and clinical response","volume":"45","author":"Mavroidis","year":"1984","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000023783_ref16","first-page":"263","article-title":"Fluphenazine, trifluoperazine, and perphenazine in Vacutainers","volume":"124","author":"Midha","year":"1981","journal-title":"Canadian Medical Association Journal"},{"key":"S0007125000023783_ref19","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.111.5.343"},{"key":"S0007125000023783_ref23","doi-asserted-by":"publisher","DOI":"10.1007\/BF00433729"},{"key":"S0007125000023783_ref13","first-page":"479","article-title":"Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine","volume":"25","author":"Marder","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"key":"S0007125000023783_ref15","first-page":"107","article-title":"Radioimmunoassay for fluphenazine in human plasma","volume":"4","author":"Midha","year":"1980","journal-title":"Communications in Psychopharmacology"},{"key":"S0007125000023783_ref10","doi-asserted-by":"publisher","DOI":"10.1007\/BF00178510"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000023783","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T22:01:12Z","timestamp":1558130472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000023783\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,5]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1991,5]]}},"alternative-id":["S0007125000023783"],"URL":"https:\/\/doi.org\/10.1192\/bjp.158.5.658","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,5]]}}}